| Schedule of segment information |
| Schedule of segment information | |
| | |
| | |
| |
| | |
Three Months Ended March 31, 2026 | |
| | |
Biotechnology Segment | | |
Technology
Segment | | |
Consolidated | |
| Sales | |
$ | – | | |
$ | 113,771 | | |
$ | 113,771 | |
| Cost of goods sold | |
| – | | |
| 45,156 | | |
| 45,156 | |
| Total operating expenses | |
| 3,870,396 | | |
| 112,683 | | |
| 3,983,259 | |
| Net loss from operations | |
$ | (3,870,396 | ) | |
$ | (44,248 | ) | |
$ | (3,914,644 | ) |
| | |
Three Months Ended March 31, 2025 | |
| | |
Biotechnology Segment | | |
Technology Segment | | |
Consolidated | |
| Sales | |
$ | – | | |
$ | 62,874 | | |
$ | 62,874 | |
| Cost of goods sold | |
| – | | |
| 45,156 | | |
| 45,156 | |
| Total operating expenses | |
| 4,014,702 | | |
| 60,000 | | |
| 4,074,702 | |
| Net loss from operations | |
$ | (4,014,702 | ) | |
$ | (42,282 | ) | |
$ | (4,056,984 | ) |
|